Jiang Wanjin, Yang Qi, Yang Xiaonan, Gan Ruijia, Hua Hongting, Ding Zhimin, Si Dongyu, Zhu Xinbei, Wang Xu, Zhang Huabing, Gao Chaobing
Department of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital of Wannan Medical College Yijishan Hospital, Wuhu, 241000, China.
Department of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Heliyon. 2024 Jul 10;10(14):e34221. doi: 10.1016/j.heliyon.2024.e34221. eCollection 2024 Jul 30.
Thirty-three synthetic driver genes of T-cell proliferation have recently been identified through genome-scale screening. However, the tumor microenvironment (TME) cell infiltration, prognosis, and response to immunotherapy mediated by multiple T cell proliferation-related genes (TRGs) in patients with head and neck squamous cell carcinoma (HNSC) remain unclear.
This study examined the genetic and transcriptional changes in 771 patients with HNSC by analyzing the TRGs from two independent datasets. Two different subtypes were analyzed to investigate their relationship with immune infiltrating cells in the TME and patient prognosis. The study also developed and validated a risk score to predict overall survival (OS). Furthermore, to enhance the clinical utility of the risk score, an accurate nomogram was constructed by combining the characteristics of this study.
The low-risk score observed in this study was associated with high levels of immune checkpoint expression and TME immune activation, indicating a favorable OS outcome. Additionally, various factors related to risk scores were depicted.
Through comprehensive analysis of TRGs in HNSC, our study has revealed the characteristics of the TME and prognosis, providing a basis for further investigation into TRGs and the development of more effective immunotherapy and targeted therapy strategies.
最近通过全基因组规模筛选鉴定出了33个T细胞增殖的合成驱动基因。然而，头颈部鳞状细胞癌（HNSC）患者中多种T细胞增殖相关基因（TRG）介导的肿瘤微环境（TME）细胞浸润、预后及对免疫治疗的反应仍不清楚。
本研究通过分析来自两个独立数据集的TRG，检测了771例HNSC患者的基因和转录变化。分析了两种不同亚型，以研究它们与TME中免疫浸润细胞及患者预后的关系。该研究还开发并验证了一个预测总生存期（OS）的风险评分。此外，为提高风险评分的临床实用性，结合本研究的特征构建了一个准确的列线图。
本研究中观察到的低风险评分与高水平的免疫检查点表达和TME免疫激活相关，表明OS结果良好。此外，还描述了与风险评分相关的各种因素。
通过对HNSC中TRG的综合分析，我们的研究揭示了TME的特征和预后，为进一步研究TRG以及开发更有效的免疫治疗和靶向治疗策略提供了依据。
